Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Alaunos Therapeutics ( (TCRT) ) has shared an announcement.
On July 1, 2025, Dale Curtis Hogue, Jr. resigned from his roles as Chief Executive Officer and board member of Alaunos Therapeutics, Inc., transitioning to a consulting role with the company. His departure was not due to any disagreements, and he will continue to provide strategic and advisory services. On July 2, 2025, Holger Weis was appointed as the new CEO, bringing extensive experience from various roles in the life sciences and pharmaceutical industries. Weis will maintain his position as Chair of the Board but will step down from committee roles. His compensation includes a base salary and stock options, aligning with the company’s equity incentive plan.
Spark’s Take on TCRT Stock
According to Spark, TipRanks’ AI Analyst, TCRT is a Neutral.
Alaunos Therapeutics’ overall score is primarily impacted by its weak financial performance with ongoing losses and negative cash flows. While the technical analysis shows some positive momentum, the negative P/E ratio and lack of dividends underscore valuation challenges. The absence of earnings call and corporate events information further limits the stock’s appeal.
To see Spark’s full report on TCRT stock, click here.
More about Alaunos Therapeutics
Average Trading Volume: 195,787
Technical Sentiment Signal: Sell
Current Market Cap: $9.28M
For detailed information about TCRT stock, go to TipRanks’ Stock Analysis page.